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Summary: The main problem in the follow-up of patients receiving organ allografts is the early differential
diagnosis of rejection episodes and infections. Serum levels of interferon gamma, a marker of T-lymphocyte
activity, were determined with an immunoradiometric assay, specific for biologically active interferon gamma
and sufficiently sensitive (20 Ü/l) for the determination of circulating interferon gamma. Neopterin, a pteridine
released from stimulated macrophages, was determined by radioimmunoassay. Both rejection crises and
infections are accompanied by distinct increases of serum neopterin (median values 124 and 128nmol/l;
N == 98). Interferon gamma levels are elevated for a short period one or two days earlier, the maximal values
during infections (median 430 U/l, ränge 120 —1220 U/l, N = 25) being higher than those during rejection
episodes (median 120 U/l, ränge < 20 —330 U/l, N = 73). Each rise of interferon gamma was followed by
an increase of neopterin, but not every neopterin increase was preceded by a interferon gamma peak. Neither
of these parameters showed an increase during deterioratiön of kidney function due to cyclosporin toxicity.
The determination of interferon gamma, a lymphokine involved in the activation of alloreactivity, reflecting
T-cell Stimulation, and the measurement of neopterin, a secretory product of activated macrophages, allows
the simple, quick and reliable monitoring of the immune Status of transplant recipients.
Konzentrationen von Neopterin und y^Interferon im Serum bei Patienten mit Herz- und Nierentransplantaten
Zusammenfassung: Wesentliche Probleme bei der Nachsorge allotransplantierter Patienten liegen in der
rechtzeitigen Diagnose von Abstoßungsreaktionen und Infektionen. Die Konzentration von -Interferon,
einem Indikator der Aktivität von T-Lymphocyten, würde in einem hochsensitiven, für biologisch aktives -
Interferon spezifischen immunoradiometrischen Test, der ausreichend empfindlich zur Messung von zirkulie-
rendem -Interferon ist, bestimmt. Neopterin, ein von aktivierten Makrophagen produziertes Pteridin, wurde
mittels Radioiinmunoassays bestimmt. Sowohl akute Abstoßungsreaktionen als auch Infektionen waren von
deutlichen Erhöhungen des Neopterin im Serum begleitet (Mediane 124 und 128 nmol/1; N = 98). -
Interferon-Konzentrationen waren kurzfristig ein bis zwei Tage früher erhöht, wobei die Maximalwerte bei
Infektionen (Mediän 430U/l, Bereich 120-l220U/l, N = 25) höher waren als bei Abstoßungsreaktionen
(Median 120 U/l, Bereich < 20-330 U/i, N = 73). Jedem -Interferon-Anstieg folgte eine merkliche Neopte-
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rin-Erhöhung, aber nicht jedem Neopterin-Anstieg ging eine entsprechende -Interferon-Erhöhung voraus.
Keine dieser Kenngrößen war bei Cyclosporin-A bedingter Verschlechterung der Nierenfunktion erhöht. Die
Bestimmung von -Interferon, einem Lyinphokin, das bei der Alloreaktivitätsaktivierung beteiligt ist und
damit ein Maß für den Grad der T-Zell-Stimulation darstellt, und Neopterin, welches die Aktivität der
Makrophagen angibt, ermöglicht die einfache, rasche und verläßliche Beurteilung des Immünstatus von
Transplantatempfängern.
Introduction
Immunological monitoring of patients with heart or
kidney allografts is decisive for the proper treatment
of possible complications. Despite significant im-
provements in the clinical management of transplant
recipients, with reduction of the corticosteroid dosage
and immunosuppression with cyclosporin A, dif-
ferential diagnosis of infections and rejections still
poses a major problem. This distinction is especially
critical, because the necessary subsequent changes in
the immunosuppressive regimen are different, de-
pending on the diagnosis. It has been shown that low
excretion of neopterin in urine is a reliable indicator
for the absence of immunological Stimuli, whereas
high excretion is found during rejection episodes and
infections (1). In vitro interferon gamma, a lympho-
kine secreted by activated T-cells, stimulates the re-
lease of neopterin from macrophages (2). We report
here the results of measurements in patient sera of
interferon gamma and neopterin, and demonstrate
that a similar regulatory pattern does exist in vivo.
The routine determinations of neopterin and inter-
feron gamma seem to be of high relevance for the
daily monitoring of transplant recipients.
Methods
Interferon gamma was determined using a modified Version of
a commercially available immunoradiometric assay (3). In this
2-step "sandwich" test interferon gamma present in the sample
is fürst bound to a monoclonal antibody coated onto a polysty-
rene bead. In the second Step, the bound interferon gamma in
turn binds to another monoclonal antibody, labelled with io-
dine-125. One of the two antibodies is specific for the active
structure, thus measuring only biologically active interferon
gamma with a sensitivity of 20 U/l.
Neopterin in serum was determined with a radioimmunosassay
(Henning, Berlin, FRG; (4)), modified to adapt its working
ränge to the elevated levels expected in transplant patients: The
sample volume was reduced from 50 to 20 and an addi-
tional Standard (320 nmol/1) was used for the construction of
the Standard curve. The incubation and Separation Steps were
äs recommended in the instructions for use.
Patients
In six patients with heart transplants, serum levels of interferon
gamma and neopterin were determined throughout the early
postoperative period of at least 5 weeks. In 63 patients with
kidney transplants (age IS—62 years), seruni levels of neopterin
were determined daily. The main reasons for kidney failure were
chronic glomerulonephritis, chronic pyelonephritis, polycystic
kidney disease and interstitial nephritis. In 28 of these patients
interferon gamma was measured daily. Six heart recipients (age
10—40 years) were transplanted due to cardiomyopathy, coron-
ary heart disease or intractably reduced ventricle function.
Sample collection started on the day of transplantatipn and
was continued until discharge from the unit. The hnmunosup-
pressive therapy consisted of cyclosporin A and prednisolone
in the majority of kidney patients, whereas according to the
Standard protocol all the heart patients received azathioprine
and anti-thymocyte globulin. In rejection cases, pulse therapy
with high-dose methylprednisolone and repeated anti-thymo-
cyte globulin was performed (tab. 1). Diagnosis of rejection in
kidney recipients was based on clinical Symptoms, laboratory
fmdings, blood chemistry, sonography and the 111-Indium-
labelled platelet uptake index. In heart transplant patients diag-.
nosis of rejection was based mainly on endoniyocardial biopsy
(5), whereas other methods such äs echocardiography and ECG
were not of decisive importance. Heart biopsies were taken
weekly, in cases of clinical impairment and after treatment by
steroid pulse therapy. In kidney patients, biopsies were taken
if necessary and analysed cytologically (fine needle aspiration
biopsy) or histologically (tru-eut biopsy). 99m-Technetium
bolus investigation, computerized tomography, and digital
subtraction angiogräphy were performed, äs appropriatC; The
diagnosis of complicating infections was based on repeated
bacteriological and serological tests such äs blöod cultures,
complement binding reaction, IgM- and IgG-titers, and virus
Isolation in addition to clinical:,symptoms.
Changes in serum neopterin were evaluated statistically, using
Studenfs t-difference test. Since data were not normally distri-
buted, median values and ranges are given. Differences between
groups were calculated using a non-parametric test.
Results
Serum neopterin levels were significantiy different
depending upon the clinical course after transplanta-
tion (fig. 1). Thirty five kidney graft recipients
without infections were classified into 3 groups ac-
cording to their clinical course. All were treated only
with cyclosporin A and steroids and/or anti-thymo-
cyte globulin (tab. 1), and none of these patients
suffered from severe infections that might have influ^
enced serum neopterin levels or required modifica-
tions in the immunsuppressive management during
the early postoperative period of up to 5 weeks.
Group I comprised 8 patients free of immunological
complications, and therefore without additional im-
munosuppressive therapy. Neopterin decreased ra-
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Tab. L Details and dosage of immunosuppressive therapy.
Protocol Kidney grafts Heart grafts
Standard
Before transplantation Cyclosporin A 5 mg/kg bw iv
During transplantation Methylprednisolone 200 mg iv
After transplantation Cyclosporin A 5 mg/kg bw iv (3 days)
Cyclosporin A po (*)
Methylprednisolone tapered down to 20 mg
Cyclosporin A 15 mg/kg bw i v
Azathioprin 4 mg/kg bw iv
Methylprednisolone 500 mg iv
Cyclosporin A 9 mg/kg bw po (*)
Methylprednisolone 3 χ 125 mg i v
Azathioprin 2 mg/kg bw iv (**)
Anti-thymocyte globulin 10 mg/kg bw i v
Rejection
Methylprednisolone 500 mg (3 days) or
Anti-thymocyte globulin 3 mg/kg bw (10 days) or
plasmapheresis
Methylprednisolone 1000 mg (3 days) or
Anti-thymocyte globulin 10 mg/kg bw (10 days)
(*) ... dosage adjusted according to blood levels
(**) ... dosage corrected according to cell count
400-
Fig. l. Time course of neopterin in serum of 35 patients after
kidney transplantation (mean values and Standard de-
viations).
Group I (N = 8) ... no complications
Group II (N = 22) ... reversible rejections
Group III (N = 5) ... graft loss due to irreversible
rejection
Significant differences from pretreatment levels are indi-
cated(* < p 0.05;** < 0.01).
D ... day of discharge (groups I & II) or graft loss
(group III). Average levels of neopterin in serum in
patients on haemodialysis before (o) and after (D) di-
alysis (see flg. 3).
pidly to levels only slightly higher than those of
healthy normal controls (N = 25).
Twenty two patients (group II) had rejection episodes
diagnosed by cliniqal Symptoms or transplant biopsy
that were reversible by appropriate therapy. A de-
crease of neopterin values was also observed, but was
delayed in comparison with group I. On the day
of discharge, neopterin levels were slightly, but not
significantly higher than for group I.
Group III comprises the five patients that lost their
transplants due to irreversible rejection. The highest
neopterin values were found on the day before graft
loss. Figure 2 shows similar, but individual data for
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Fig. 2. Individual time courses of serum neopterin in 6 patients
after heart transplantation. One patient ( )
died of acute rejection.
D...day of discharge or graft loss.
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Fig. 3. Neopterin and creatinine serum concentrations before
(o) and after (o) haemodialysis (5-6 hours) in 33
patients with no apparent imraunological activity.
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six heart transplant patients. To Interpret the pre-
transplant levels of neopterin in serum, values for
patients with chronic renal failure and the effects of
haemodialysis are shown in figure 3. After dialysis,
concentrations of neopterin were decreased by about
50%, but they were still 5-fold higher than normal
controls. No quantitative correlation between the re-
duction by haemodialysis of senim neopterin and
creatinine, blood urea nitrogen or uric acid was
found.
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Fig. 4. Time course of interferon gamma (o) and neopterin (o) serum levels.
a) Patient with kidney graft; uncomplicated elinical course. Low interferon gamma and neopterin quickly decreasing
after transplantation.
b) Patient with kidney graft; several reversible rejection episodes ®. Only slight elevations in interferon gamma büt
marked increases of neopterin at time of Symptoms or biopsy (the last rejection episode was pröven histologically).
„ Decrease of neopterin levels with elinical improvement düe to therapy.
c) Heart recipient, died of intractable rejection ®. Moderate increase of mterferon gamina followed by increase of
neopterin. Five days before death, a biopsy showed no signs of rejectipn, and interferon gamma äs well äs neopterin
levels were low.
d) Patient with kidney graft; septic complications, pröven by «epeated positive bacterial blood cultures ©.
Pronounced interferon gamma peaks in contrast to rejection episodes.
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Tab. 2. Interferon gamma and neopterin serum levels. Values
in 25 healthy controls, 65 kidney and 6 heart recipients
with 73 rejection episodes and 25 infections. Values
given are median and ränge.
Interferon gamma
(U/l)
Neopterin
(nmol/1)
Acute rejections
day of diagnosis
2 days later
120 (n.d.-330) (l, 2) 124 (39-495) (1)
80 (n.d.-l 50) (l, 3) 121 (48-560) (1)
Infections
day of diagnosis 430 (120 -1220) (1) 62 (23 -129) (1)
2 days later 160 (n.d.- 470) (1,4) 128 (46-520) (l, 5)
Healthy controls ränge n.d. —35 5(0.4-10.2)
n.d. ... not detectable (< 20 U/l)
(1) ... higher than normal controls (p < 0.01)
(2)... lower than at the day of diagnosis of infection (p < 0.01)
(3) ... lower than 2 days earlier (p < 0.05)
(4) ... lower than 2 days earlier (p < 0.01)
(5) ... higher than*2 days earlier (p < 0.02)
Data from patients with rejections and infectious
complications are summarized in table 2. In all
patients with severe infection episodes (viral, N = 8,
and bacterial, N = 17) distinct peaks of Interferon
gamma were observed, followed l to 2 days later
by marked increases of neopterin. In contrast, less
pronounced or unmeasurable increments of inter-
feron gamma were seen during acute rejection episo-
des, whereas neopterin peak levels were äs high äs
those during infections. To ilhzstrate the relation be-
tween neopterin and interferon gamma in serum, four
cases are showü in figures 4 a—d (details are given
in the legends).
Discussion
The clinical value of daily measurements of neopterin
excretion in urine has been demonstrated in kidney
transplantations and other clinical situations (1). Re-
cently, it has been shöwn that the neopterin is released
by maerophages when they are stimulated by inter-
feron gamma produced from activated T-lymphocy-
tes (2). These in vitro results have prompted us to
investigate the use of serum neopterin for the moni-
toring of transplant patients and to search för a
similar regulatory pattern in vivo. Case reports have
been published (5) in which measurable interferon
gamma levels in serum were found associated with
stimulations of the immune System, !both during infec-
tions and in some but not all rejection crises. A
clinically uiicomplicated posttransplant course was
almost invariably associated with rapidly decreasing
neopterin levels in kidney patients and with stable
and low levels for heart recipients. This dissimilarity
is probably the consequence of different pretrans-
plant levels. Patients on haemodialysis have neopterin
values much higher than normal controls even
without any apparent immunological Stimuli, reflect-
ing the predominantly renal excretion of pteridines.
The onset of acute rejection episodes were in all cases
associated with rising neopterin levels or, in the case
of some kidney recipients, with delay or cessation of
the decline expected for an immunologically uncom-
plicated course. The relative small increase of neop-
terin in the heart patient with an irreversible rejection
is probably due to the early end of function of this
vital organ, which contrasts with rejection episodes
in kidney recipients that are not of immediate danger
to life. Interferon gamma was clearly elevated for a
short period at the onset of infections, but only to a
lower extent during rejection crises. It thus appears
that the daily monitoring of interferon gamma and
neopterin levels in serum are useful for the detection
of immunological activations. Similarly, urinary neo-
pterin excretion has been shown to allow the early
diagnosis of acute rejections and viral infections with
very few false positive results (1).
With the development of a quick and reliable assay
sufficiently sensitive to detect interferon gamma in
peripheral blood, it is now possible to determine a
lymphokine that controls the activation of maero-
phages. This offers an additional advantage, since
elevations of interferon gamma preceeded the neo-
pterin increases by one or two days, äs expected
• from in vitro experiments. Without exception, every
increase of interferon gamma over 120 U/l was fol-
lowed by a significant rise in neopterin. From a
practical point of view its determination in serum
seems to be at least äs useful äs the determination of
the urinary excretion, with the additional advantage
of being independent of urine output. Furthermore,
interferon gamma might help in the differential diag-
nosis of rejection and infection, since the majority of
infections showed peak levels above the maximal
values measured during acute rejections.
In conclusion, the simultaneous daily determination
of interferon gamma and neopterin in the early post-
operative period seems to be a useful tool for dif-
ferential diagnosis of immunological complications
and for monitoring their treatment in kidney and
heart transplant patients.
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